SPMS
MCID: SCN036
MIFTS: 52

Secondary Progressive Multiple Sclerosis (SPMS)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Secondary Progressive Multiple Sclerosis

MalaCards integrated aliases for Secondary Progressive Multiple Sclerosis:

Name: Secondary Progressive Multiple Sclerosis 12 55 15
Multiple Sclerosis, Secondary Progressive 73
Multiple Sclerosis, Chronic Progressive 44
Secondary-Progressive Ms 12
Spms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050783
MeSH 44 D020528
UMLS 73 C0751965

Summaries for Secondary Progressive Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterised by a worsening of disability, rather than by relapses followed by recovery, which progressively worsens until a steady progression of disability replaces the cycles of attacks.

MalaCards based summary : Secondary Progressive Multiple Sclerosis, also known as multiple sclerosis, secondary progressive, is related to multiple sclerosis and primary progressive multiple sclerosis. An important gene associated with Secondary Progressive Multiple Sclerosis is HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1), and among its related pathways/superpathways are PEDF Induced Signaling and Akt Signaling. The drugs 4-Aminopyridine and Dimethyl fumarate have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and spinal cord, and related phenotypes are cellular and behavior/neurological

Related Diseases for Secondary Progressive Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Secondary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 multiple sclerosis 30.6 CCL2 CCR5 CXCL10 CXCR3 IFNB1 IFNG
2 primary progressive multiple sclerosis 29.9 IFNB1 IL10 MBP MMP9 S100B
3 encephalitis 29.9 CCL2 CCR5 CXCL10
4 arthritis 29.7 CCL2 IFNG IL10 MMP9
5 relapsing-remitting multiple sclerosis 29.6 HNRNPA1 IFNB1 IFNG IL10 MBP MMP9
6 viral infectious disease 29.2 CCR5 CD40LG CXCL10 IFNB1 IFNG IL10
7 scapuloperoneal myopathy, x-linked dominant 11.8
8 degos 'en cocarde' erythrokeratoderma 10.6
9 niemann-pick disease 10.3
10 epilepsy 10.3
11 temporal lobe epilepsy 10.3
12 lentigo maligna melanoma 10.3 MMP9 S100B
13 intracranial cysts 10.3 ENO2 S100B
14 acute transverse myelitis 10.3 IL10 MMP9
15 bednar tumor 10.3 ENO2 S100B
16 folliculotropic mycosis fungoides 10.2 CCR3 CXCR3
17 finger agnosia 10.2 ENO2 MBP
18 epithelioid malignant peripheral nerve sheath tumor 10.2 ENO2 S100B
19 ossifying fibromyxoid tumor 10.2 ENO2 S100B
20 retroperitoneal neuroblastoma 10.2 ENO2 IFNB1
21 chromoblastomycosis 10.2 CXCR3 MMP9
22 head injury 10.2 ENO2 S100B
23 transverse myelitis 10.2 IL10 MBP MMP9
24 bacterial meningitis 10.2 IL10 MMP9 S100B
25 appendicitis 10.2 ENO2 IL10 MMP9
26 balo concentric sclerosis 10.2 IFNB1 MBP
27 diabetic foot ulcers 10.2 CCL2 MMP9
28 palladium allergic contact dermatitis 10.2 CCL2 IL10
29 dementia 10.2
30 opsoclonus-myoclonus syndrome 10.2 CXCL10 CXCR3
31 neurosyphilis 10.2 CXCL10 IL10
32 cephalosporin allergy 10.2 IFNG IL10
33 optic nerve glioma 10.2 ENO2 MBP S100B
34 cerebral primitive neuroectodermal tumor 10.2 ENO2 IFNB1 S100B
35 acrodermatitis chronica atrophicans 10.2 CD40LG CXCL10
36 mucocutaneous leishmaniasis 10.2 CCR5 IL10
37 middle cerebral artery infarction 10.2 CD40LG ENO2 S100B
38 hyperlucent lung 10.2 IFNG IL10
39 meningeal melanocytoma 10.2 CD40LG ENO2 S100B
40 ocular toxoplasmosis 10.1 CCR5 CD40LG
41 pineocytoma 10.1 ENO2 S100B
42 nickel allergic contact dermatitis 10.1 IFNG IL10
43 oligodendroglioma 10.1 ENO2 MBP S100B
44 tuberculous meningitis 10.1 CCL2 ENO2 MMP9
45 baylisascariasis 10.1 IFNG IL10
46 extrinsic allergic alveolitis 10.1 CCL2 CXCR3 IL10
47 penicillin allergy 10.1 IFNG IL10
48 tick-borne encephalitis 10.1 CCR5 CXCL10 IL10
49 intermediate uveitis 10.1 CXCR3 IFNG IL10
50 lymphoproliferative syndrome 2 10.1 CD40LG CXCL10 CXCR3

Graphical network of the top 20 diseases related to Secondary Progressive Multiple Sclerosis:



Diseases related to Secondary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Secondary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Secondary Progressive Multiple Sclerosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.15 CCR3 CCR5 CD40LG CXCL10 CXCR3 ENO2
2 behavior/neurological MP:0005386 10.06 CCR5 ENO2 IFNG IL10 MBP MMP9
3 hematopoietic system MP:0005397 10.06 CCR3 CCR5 CD40LG CXCL10 CXCR3 IFNB1
4 homeostasis/metabolism MP:0005376 10.03 CCR3 CCR5 CD40LG CXCL10 CXCR3 IFNB1
5 immune system MP:0005387 9.93 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3
6 neoplasm MP:0002006 9.5 CCR5 CXCR3 IFNB1 IFNG IL10 MMP9
7 nervous system MP:0003631 9.32 CCR5 CD40LG CXCL10 ENO2 IFNB1 IFNG

Drugs & Therapeutics for Secondary Progressive Multiple Sclerosis

Drugs for Secondary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 4,Phase 3 504-24-5 1727
2
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3 624-49-7 637568 5271565
3
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5 Potassium Channel Blockers Phase 4,Phase 3
6 Dermatologic Agents Phase 4,Phase 3,Phase 1
7 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
8 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
9 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1
10 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 glucocorticoids Phase 4,Phase 3,Phase 1
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
15
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 1 302-25-0
16
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1 83-43-2 6741
17
Prednisolone Approved, Vet_approved Phase 3,Phase 1 50-24-8 5755
18
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
19
Methylprednisolone hemisuccinate Approved Phase 3,Phase 1 2921-57-5
20
Simvastatin Approved Phase 3,Phase 2 79902-63-9 54454
21
Natalizumab Approved, Investigational Phase 3,Phase 2,Phase 1 189261-10-7
22
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
24
Prednisolone hemisuccinate Experimental Phase 3,Phase 1 2920-86-7
25 Alkylating Agents Phase 3
26 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Alkylating Phase 3
28 Prednisolone acetate Phase 3,Phase 1
29 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
30 Antiemetics Phase 3,Phase 2,Phase 1
31 Neuroprotective Agents Phase 3,Phase 2,Phase 1
32 Antirheumatic Agents Phase 3,Phase 1,Phase 2
33 Autonomic Agents Phase 3,Phase 2,Phase 1
34 Protective Agents Phase 3,Phase 2,Phase 1
35 Methylprednisolone acetate Phase 3,Phase 1
36 Vitamins Phase 2, Phase 3,Phase 1,Not Applicable
37 Thioctic Acid Phase 2, Phase 3,Phase 1
38 Vitamin B9 Phase 2, Phase 3,Phase 1
39 Alpha-lipoic Acid Phase 2, Phase 3,Phase 1
40 Folate Phase 2, Phase 3,Phase 1
41 Antioxidants Phase 2, Phase 3,Phase 1
42 Trace Elements Phase 2, Phase 3,Phase 1,Not Applicable
43 Micronutrients Phase 2, Phase 3,Phase 1,Not Applicable
44 Vitamin B Complex Phase 2, Phase 3,Phase 1
45 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3,Phase 2
46 Anticholesteremic Agents Phase 3,Phase 2
47 Lipid Regulating Agents Phase 3,Phase 2,Phase 1
48 Antimetabolites Phase 3,Phase 2,Phase 1
49 Hypolipidemic Agents Phase 3,Phase 2,Phase 1
50 Antiviral Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
2 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
3 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
4 BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Completed NCT03269175 Phase 4
5 Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Terminated NCT01411514 Phase 4 Prednisone;Placebo
6 A Study for Patients With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
7 Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis Completed NCT00241254 Phase 3 Cyclophosphamide (drug);Methylprednisolone (drug)
8 Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Completed NCT01188811 Phase 2, Phase 3 lipoic acid;Placebo
9 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Completed NCT01917019 Phase 3 Placebo;BIIB041 (fampridine)
10 Multiple Sclerosis-Simvastatin Trial 2 Recruiting NCT03387670 Phase 3 Simvastatin;Placebo
11 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) Active, not recruiting NCT01665144 Phase 3 BAF312;Placebo
12 Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis Active, not recruiting NCT01433497 Phase 3 Masitinib;Placebo
13 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3 MD1003 100mg capsule
14 Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP) Not yet recruiting NCT03653273 Phase 3 DMT continuation
15 A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Terminated NCT01416181 Phase 3 natalizumab;Placebo
16 Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00468611 Phase 3 MBP8298
17 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
18 Study Evaluating Mitoxantrone in Multiple Sclerosis Terminated NCT00146159 Phase 3 Mitoxantrone
19 A Study for Patients With Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3 dirucotide
20 Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) Withdrawn NCT00313976 Phase 3 Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
21 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
22 Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis Completed NCT02228213 Phase 2 Saline
23 A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis Completed NCT00257855 Phase 2 Lamotrigine
24 Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis Completed NCT00647348 Phase 2 Simvastatin;Placebo
25 Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis Completed NCT01450488 Phase 2 masitinib;masitinib
26 Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis Completed NCT01684761 Phase 2
27 Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis Completed NCT01056471 Phase 1, Phase 2
28 Natalizumab Treatment of Progressive Multiple Sclerosis Completed NCT01077466 Phase 2 Natalizumab
29 Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Completed NCT00342134 Phase 2
30 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Completed NCT01982942 Phase 2 ibudilast;Placebo oral capsule
31 Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis Completed NCT01191996 Phase 1, Phase 2
32 Treatment of Multiple Sclerosis Using Over the Counter Inosine Completed NCT00067327 Phase 2 Inosine
33 Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) Completed NCT00086671 Phase 2 ABT-874/Human monoclonal antibody against IL-12;Placebo
34 A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) Completed NCT00436826 Phase 2 Cladribine;Placebo;Interferon-beta (IFN-beta)
35 Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis Completed NCT01517282 Phase 1, Phase 2
36 Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) Recruiting NCT02308137 Phase 2 Domperidone
37 Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease Recruiting NCT02649985 Phase 1, Phase 2 [F-18]PBR06
38 Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Recruiting NCT01466114 Phase 2 estriol;Norethindrone
39 ACTH in Progressive Forms of MS Recruiting NCT01950234 Phase 2 ACTH;Placebo
40 A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients Recruiting NCT03560739 Phase 2 OMB157
41 MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial Active, not recruiting NCT01910259 Phase 2 Amiloride;Riluzole;Fluoxetine;Placebo
42 Autologous Mesenchymal Stromal Cells for Multiple Sclerosis Active, not recruiting NCT02495766 Phase 1, Phase 2 XCEL-MC-ALPHA;Placebo
43 Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS Not yet recruiting NCT03696485 Phase 1, Phase 2
44 Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) Terminated NCT01212094 Phase 1, Phase 2 Rituximab
45 Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) Withdrawn NCT01181089 Phase 1, Phase 2
46 Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01381354 Phase 1
47 Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) Completed NCT00559702 Phase 1 natalizumab
48 A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Completed NCT02253264 Phase 1 Rituximab
49 Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS Completed NCT00813969 Phase 1
50 Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis Completed NCT00997438 Phase 1

Search NIH Clinical Center for Secondary Progressive Multiple Sclerosis

Cochrane evidence based reviews: multiple sclerosis, chronic progressive

Genetic Tests for Secondary Progressive Multiple Sclerosis

Anatomical Context for Secondary Progressive Multiple Sclerosis

MalaCards organs/tissues related to Secondary Progressive Multiple Sclerosis:

41
Brain, T Cells, Spinal Cord, Lung, Skin, Bone, Ovary

Publications for Secondary Progressive Multiple Sclerosis

Articles related to Secondary Progressive Multiple Sclerosis:

(show top 50) (show all 267)
# Title Authors Year
1
Natalizumab in secondary progressive multiple sclerosis. ( 29545068 )
2018
2
Progressive visual function impairment as the predominant symptom of the transition phase to secondary progressive multiple sclerosis: A case report. ( 29957351 )
2018
3
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. ( 29576505 )
2018
4
Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis: a protocol for a feasibility randomised controlled trial. ( 28770099 )
2018
5
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. ( 29545067 )
2018
6
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. ( 29968175 )
2018
7
Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. ( 29768414 )
2018
8
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. ( 29846780 )
2018
9
Siponimod for the treatment of secondary progressive multiple sclerosis. ( 30517042 )
2018
10
High-frequency rTMS and iTBS for spasticity management in secondary-progressive multiple sclerosis. ( 30472778 )
2018
11
Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis. ( 30477834 )
2018
12
Olfactory function and cognition in relapsing-remitting and secondary-progressive multiple sclerosis. ( 30273697 )
2018
13
Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis. ( 30214633 )
2018
14
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. ( 30166303 )
2018
15
Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. ( 30090637 )
2018
16
Prospects of siponimod in secondary progressive multiple sclerosis. ( 30038666 )
2018
17
Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study. ( 29177070 )
2017
18
Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort. ( 29111873 )
2017
19
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. ( 28429241 )
2017
20
Urinary Excretion of Aluminium and Silicon in Secondary Progressive Multiple Sclerosis. ( 29128442 )
2017
21
Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis. ( 28801580 )
2017
22
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. ( 28594298 )
2017
23
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. ( 28045953 )
2017
24
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. ( 28600189 )
2017
25
Markers of oxidative/nitrative damage of plasma proteins correlated with EDSS and BDI scores in patients with secondary progressive multiple sclerosis. ( 28521618 )
2017
26
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. ( 29138536 )
2017
27
Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. ( 28905255 )
2017
28
Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? ( 27753181 )
2017
29
Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. ( 28145395 )
2017
30
Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. ( 28572730 )
2017
31
Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. ( 28838904 )
2017
32
Corpus callosum atrophy as a marker of clinically meaningful cognitive decline in secondary progressive multiple sclerosis. Impact on employment status. ( 28601572 )
2017
33
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. ( 28396953 )
2017
34
Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis. ( 27339072 )
2017
35
Expression of DNA methylation genes in secondary progressive multiple sclerosis. ( 26711572 )
2016
36
Secondary Progressive Multiple Sclerosis: Definition and Measurement. ( 27166830 )
2016
37
Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. ( 27996064 )
2016
38
Defining secondary progressive multiple sclerosis. ( 27401521 )
2016
39
Brain perfusion imaging with voxel-based analysis in secondary progressive multiple sclerosis patients with a moderate to severe stage of disease: a boon for the workforce. ( 27229156 )
2016
40
Corrigendum to "Expression of DNA methylation genes in secondary progressive multiple sclerosis" [J. Neuroimmunol. 290 (2016 Jan. 15) 66-9]. ( 27235362 )
2016
41
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. ( 26788129 )
2016
42
Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study. ( 27636543 )
2016
43
The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients. ( 27507559 )
2016
44
Patterns of white matter damage are non-random and associated with cognitive function in secondary progressive multiple sclerosis. ( 27408797 )
2016
45
HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS. ( 27917400 )
2016
46
Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. ( 26943957 )
2016
47
The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences. ( 27803641 )
2016
48
Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis. ( 27620894 )
2016
49
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. ( 27003945 )
2016
50
Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple Sclerosis. ( 27739247 )
2016

Variations for Secondary Progressive Multiple Sclerosis

ClinVar genetic disease variations for Secondary Progressive Multiple Sclerosis:

6 (show all 38)
# Gene Variation Type Significance SNP ID Assembly Location
1 HNRNPA1 NM_002136.3(HNRNPA1): c.787T> C (p.Phe263Leu) single nucleotide variant Likely pathogenic rs483353022 GRCh37 Chromosome 12, 54677631: 54677631
2 HNRNPA1 NM_002136.3(HNRNPA1): c.787T> C (p.Phe263Leu) single nucleotide variant Likely pathogenic rs483353022 GRCh38 Chromosome 12, 54283847: 54283847
3 HNRNPA1 NM_002136.3(HNRNPA1): c.793A> G (p.Asn265Asp) single nucleotide variant Likely pathogenic rs483353023 GRCh37 Chromosome 12, 54677637: 54677637
4 HNRNPA1 NM_002136.3(HNRNPA1): c.793A> G (p.Asn265Asp) single nucleotide variant Likely pathogenic rs483353023 GRCh38 Chromosome 12, 54283853: 54283853
5 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> C (p.Phe273Leu) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
6 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> C (p.Phe273Leu) single nucleotide variant Pathogenic rs483353028 GRCh38 Chromosome 12, 54283877: 54283877
7 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> G (p.Phe273Val) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
8 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> G (p.Phe273Val) single nucleotide variant Pathogenic rs483353028 GRCh38 Chromosome 12, 54283877: 54283877
9 HNRNPA1 NM_002136.3(HNRNPA1): c.823C> T (p.Pro275Ser) single nucleotide variant Likely pathogenic rs483353029 GRCh37 Chromosome 12, 54677667: 54677667
10 HNRNPA1 NM_002136.3(HNRNPA1): c.823C> T (p.Pro275Ser) single nucleotide variant Likely pathogenic rs483353029 GRCh38 Chromosome 12, 54283883: 54283883
11 HNRNPA1 NM_002136.3(HNRNPA1): c.831G> T (p.Lys277Asn) single nucleotide variant Likely pathogenic rs483353030 GRCh37 Chromosome 12, 54677675: 54677675
12 HNRNPA1 NM_002136.3(HNRNPA1): c.831G> T (p.Lys277Asn) single nucleotide variant Likely pathogenic rs483353030 GRCh38 Chromosome 12, 54283891: 54283891
13 HNRNPA1 NM_002136.3(HNRNPA1): c.841T> C (p.Phe281Leu) single nucleotide variant Pathogenic rs483353031 GRCh37 Chromosome 12, 54677685: 54677685
14 HNRNPA1 NM_002136.3(HNRNPA1): c.841T> C (p.Phe281Leu) single nucleotide variant Pathogenic rs483353031 GRCh38 Chromosome 12, 54283901: 54283901
15 HNRNPA1 NM_002136.3(HNRNPA1): c.850A> G (p.Arg284Gly) single nucleotide variant Likely pathogenic rs483353032 GRCh37 Chromosome 12, 54677694: 54677694
16 HNRNPA1 NM_002136.3(HNRNPA1): c.850A> G (p.Arg284Gly) single nucleotide variant Likely pathogenic rs483353032 GRCh38 Chromosome 12, 54283910: 54283910
17 HNRNPA1 NM_002136.3(HNRNPA1): c.853A> G (p.Ser285Gly) single nucleotide variant Likely pathogenic rs483353033 GRCh37 Chromosome 12, 54677697: 54677697
18 HNRNPA1 NM_002136.3(HNRNPA1): c.853A> G (p.Ser285Gly) single nucleotide variant Likely pathogenic rs483353033 GRCh38 Chromosome 12, 54283913: 54283913
19 HNRNPA1 NM_002136.3(HNRNPA1): c.884A> G (p.Tyr295Cys) single nucleotide variant Likely pathogenic rs483353034 GRCh37 Chromosome 12, 54677728: 54677728
20 HNRNPA1 NM_002136.3(HNRNPA1): c.884A> G (p.Tyr295Cys) single nucleotide variant Likely pathogenic rs483353034 GRCh38 Chromosome 12, 54283944: 54283944
21 HNRNPA1 NM_002136.3(HNRNPA1): c.886T> C (p.Phe296Leu) single nucleotide variant Likely pathogenic rs483353035 GRCh37 Chromosome 12, 54677730: 54677730
22 HNRNPA1 NM_002136.3(HNRNPA1): c.886T> C (p.Phe296Leu) single nucleotide variant Likely pathogenic rs483353035 GRCh38 Chromosome 12, 54283946: 54283946
23 HNRNPA1 NM_002136.3(HNRNPA1): c.896C> T (p.Pro299Leu) single nucleotide variant Likely pathogenic rs483353036 GRCh37 Chromosome 12, 54677740: 54677740
24 HNRNPA1 NM_002136.3(HNRNPA1): c.896C> T (p.Pro299Leu) single nucleotide variant Likely pathogenic rs483353036 GRCh38 Chromosome 12, 54283956: 54283956
25 HNRNPA1 NM_002136.3(HNRNPA1): c.898C> T (p.Arg300Ter) single nucleotide variant Likely pathogenic rs483353037 GRCh37 Chromosome 12, 54677742: 54677742
26 HNRNPA1 NM_002136.3(HNRNPA1): c.898C> T (p.Arg300Ter) single nucleotide variant Likely pathogenic rs483353037 GRCh38 Chromosome 12, 54283958: 54283958
27 HNRNPA1 NM_002136.3(HNRNPA1): c.901A> G (p.Asn301Asp) single nucleotide variant Likely pathogenic rs483353039 GRCh37 Chromosome 12, 54677745: 54677745
28 HNRNPA1 NM_002136.3(HNRNPA1): c.901A> G (p.Asn301Asp) single nucleotide variant Likely pathogenic rs483353039 GRCh38 Chromosome 12, 54283961: 54283961
29 HNRNPA1 NM_002136.3(HNRNPA1): c.902A> G (p.Asn301Ser) single nucleotide variant Likely pathogenic rs483353038 GRCh37 Chromosome 12, 54677746: 54677746
30 HNRNPA1 NM_002136.3(HNRNPA1): c.902A> G (p.Asn301Ser) single nucleotide variant Likely pathogenic rs483353038 GRCh38 Chromosome 12, 54283962: 54283962
31 HNRNPA1 NM_002136.3(HNRNPA1): c.922T> G (p.Ser308Ala) single nucleotide variant Likely benign rs483353040 GRCh37 Chromosome 12, 54678056: 54678056
32 HNRNPA1 NM_002136.3(HNRNPA1): c.922T> G (p.Ser308Ala) single nucleotide variant Likely benign rs483353040 GRCh38 Chromosome 12, 54284272: 54284272
33 HNRNPA1 NM_002136.3(HNRNPA1): c.941A> G (p.Tyr314Cys) single nucleotide variant Likely benign rs483353041 GRCh37 Chromosome 12, 54678075: 54678075
34 HNRNPA1 NM_002136.3(HNRNPA1): c.941A> G (p.Tyr314Cys) single nucleotide variant Likely benign rs483353041 GRCh38 Chromosome 12, 54284291: 54284291
35 HNRNPA1 NM_002136.3(HNRNPA1): c.950G> A (p.Gly317Asp) single nucleotide variant Likely benign rs483353042 GRCh38 Chromosome 12, 54284300: 54284300
36 HNRNPA1 NM_002136.3(HNRNPA1): c.950G> A (p.Gly317Asp) single nucleotide variant Likely benign rs483353042 GRCh37 Chromosome 12, 54678084: 54678084
37 HNRNPA1 NM_002136.3(HNRNPA1): c.958T> C (p.Phe320Leu) single nucleotide variant Likely benign rs483353043 GRCh37 Chromosome 12, 54678092: 54678092
38 HNRNPA1 NM_002136.3(HNRNPA1): c.958T> C (p.Phe320Leu) single nucleotide variant Likely benign rs483353043 GRCh38 Chromosome 12, 54284308: 54284308

Expression for Secondary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Secondary Progressive Multiple Sclerosis.

Pathways for Secondary Progressive Multiple Sclerosis

Pathways related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3
2
Show member pathways
13.3 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3
3
Show member pathways
13.17 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3
4
Show member pathways
13.12 CCL2 CCR5 CD40LG CXCL10 IFNB1 IFNG
5
Show member pathways
12.94 CCL2 CCR3 CCR5 IFNB1 MMP9
6
Show member pathways
12.9 CCL2 CXCL10 IFNB1 IFNG IL10
7
Show member pathways
12.78 CCL2 CCR3 CCR5 CXCL10 CXCR3
8 12.48 ENO2 MBP S100B SLC1A3
9 12.44 CCL2 CD40LG CXCL10 IFNG IL10
10
Show member pathways
12.33 CCR5 CD40LG IFNG IL10
11
Show member pathways
12.3 CCR5 IFNB1 IFNG IL10
12
Show member pathways
12.23 CCL2 CXCL10 IFNG MMP9
13
Show member pathways
12.15 CCR5 CD40LG IFNG IL10
14
Show member pathways
12.04 CCL2 CCR3 CCR5 CXCL10 CXCR3 MMP9
15 11.98 CCL2 IFNG MMP9
16 11.88 CCR3 IFNG IL10
17 11.87 CCL2 IL10 MMP9
18 11.78 CCL2 CXCL10 IFNB1 MMP9
19 11.74 CCR5 IFNB1 IFNG IL10
20 11.73 CCL2 CXCL10 IFNG MBP MMP9
21 11.7 CXCR3 IFNG IL10
22 11.66 IFNB1 IFNG IL10
23
Show member pathways
11.62 CCL2 CCR3 CCR5 CXCL10 CXCR3
24 11.57 CCL2 CCR3 MMP9
25
Show member pathways
11.56 CD40LG IFNG MMP9
26 11.36 CCL2 CCR5 CXCL10 IL10
27 11.31 CCL2 CD40LG IFNG IL10
28 11.29 CXCL10 IFNB1 IFNG
29 11.19 CCL2 CD40LG MMP9
30 11.12 IFNB1 IFNG IL10
31 11.1 CCL2 CD40LG CXCL10 IL10
32 10.87 CCL2 CXCL10 IFNG IL10 MMP9
33 10.65 CCL2 CCR3 IFNG MMP9

GO Terms for Secondary Progressive Multiple Sclerosis

Cellular components related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 CCL2 CD40LG CXCL10 IFNB1 IFNG IL10
2 cell surface GO:0009986 9.55 CCR5 CD40LG CXCR3 MBP SLC1A3
3 external side of plasma membrane GO:0009897 9.35 CCR3 CCR5 CD40LG CXCL10 CXCR3
4 extracellular space GO:0005615 9.28 CCL2 CD40LG CXCL10 ENO2 IFNB1 IFNG

Biological processes related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.91 CCL2 CD40LG CXCL10 IFNB1 IFNG IL10
2 cytokine-mediated signaling pathway GO:0019221 9.85 CCL2 CCR5 CXCL10 IFNB1 IL10 MMP9
3 chemotaxis GO:0006935 9.8 CCL2 CCR3 CCR5 CXCL10 CXCR3
4 cell surface receptor signaling pathway GO:0007166 9.8 CCL2 CCR5 CXCL10 CXCR3 IFNB1 IFNG
5 cellular response to lipopolysaccharide GO:0071222 9.78 CCL2 CCR5 CXCL10 IL10
6 response to virus GO:0009615 9.73 CXCL10 IFNB1 IFNG
7 calcium-mediated signaling GO:0019722 9.7 CCR3 CCR5 CXCR3
8 inflammatory response GO:0006954 9.7 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3
9 B cell differentiation GO:0030183 9.69 CD40LG IFNB1 IL10
10 humoral immune response GO:0006959 9.67 CCL2 IFNB1 IFNG
11 cell chemotaxis GO:0060326 9.65 CCL2 CCR3 CCR5 CXCL10 CXCR3
12 B cell proliferation GO:0042100 9.63 CD40LG IFNB1 IL10
13 positive regulation of synaptic transmission GO:0050806 9.58 S100B SLC1A3
14 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.57 IFNB1 IFNG
15 T cell chemotaxis GO:0010818 9.55 CXCL10 CXCR3
16 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.54 IL10 MBP
17 chemokine-mediated signaling pathway GO:0070098 9.35 CCL2 CCR3 CCR5 CXCL10 CXCR3
18 immune response GO:0006955 9.28 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3

Molecular functions related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine binding GO:0019956 9.5 CCR3 CCR5 CXCR3
2 C-C chemokine binding GO:0019957 9.43 CCR3 CCR5 CXCR3
3 C-C chemokine receptor activity GO:0016493 9.33 CCR3 CCR5 CXCR3
4 chemokine receptor activity GO:0004950 9.13 CCR3 CCR5 CXCR3
5 cytokine activity GO:0005125 9.1 CCL2 CD40LG CXCL10 IFNB1 IFNG IL10

Sources for Secondary Progressive Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....